A phase 2 randomized clinical trial of abiraterone plus ADT, apalutamide, or abiraterone and apalutamide in patients with advanced prostate cancer with non-castrate testosterone levels (LACOG 0415)

Artigo Acesso aberto

Produção Nacional Revisado por pares

A phase 2 randomized clinical trial of abiraterone plus ADT, apalutamide, or abiraterone and apalutamide in patients with advanced prostate cancer with non-castrate testosterone levels (LACOG 0415)

2021; Elsevier BV; Volume: 158; Linguagem: Inglês

10.1016/j.ejca.2021.08.032

ISSN

1879-0852

Autores

Fernando Cotait Maluf, Fabio A. Schutz, Eduardo Cronemberger, Murilo Luz, Suelen P. S. Martins, David Q.B. Muniz, Diogo Assed Bastos, Flavio Mavignier Cárcano, Òren Smaletz, Andrey Soares, Fábio Affonso Peixoto, Andrea Juliana Pereira de Santana Gomes, Felipe Melo Cruz, Fábio Franke, Daniel Herchenhorn, Telma Santos, Vanessa de Carvalho Fabrício, Rosemarie Gidekel, Gustavo Werutsky, Rafaela Gomes de Jesus, Vinícius Carrera Souza, André P. Fay,

Tópico(s)

Hormonal and reproductive studies

Resumo

Androgen deprivation therapy (ADT) combined with apalutamide, abiraterone acetate plus prednisone, enzalutamide, or docetaxel are the standard treatments for advanced castration-sensitive prostate cancer (CSPC). We investigated ADT-free alternatives for advanced CSPC.

Ver no editor

Altmetric

PlumX

Entrar

Lembrar minha senha

Receber meu e-mail de confirmação

A phase 2 randomized clinical trial of abiraterone plus ADT, apalutamide, or abiraterone and apalutamide in patients with advanced prostate cancer with non-castrate testosterone levels (LACOG 0415)